Group 1 - ARK Innovation ETF (ARKK) has reached a 52-week high, increasing approximately 92.4% from its 52-week low of $36.85 per share [1] - The ETF focuses on "disruptive innovation," investing in companies involved in DNA technologies, automation, robotics, energy storage, artificial intelligence, and Fintech [1] - Cathie Wood, CEO of Ark Investment Management, has made significant moves by purchasing shares of CRISPR Therapeutics AG and Beam Therapeutics Inc., while selling shares of 908 Devices Inc. and Roku Inc., indicating a bullish stance on gene-editing technologies [2] Group 2 - ARKK shows a weighted alpha of 60.23 and a 20-day volatility of 29.55%, suggesting potential for continued strength and gains for investors [4] - Despite market turbulence, Cathie Wood maintains a positive outlook on the transformative power of emerging technologies [3]

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of participati ...

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of participati ...

Core Insights - CRISPR Therapeutics has entered a collaboration with Sirius Therapeutics to develop and commercialize novel siRNA therapies, specifically targeting thromboembolic disorders [1][3] - The lead candidate from this partnership, SRSD107, has shown promising results in early studies, indicating potential as a best-in-class therapy for thromboembolism [5][6] Financial Terms of the Collaboration - CRISPR Therapeutics will make an upfront cash payment of $25 million and $70 million in equity to Sirius Therapeutics, with both companies sharing development costs and profits equally [3][4] - CRISPR will handle commercialization in the U.S., while Sirius will lead in Greater China [3] Development Status of SRSD107 - Phase I studies have demonstrated over 93% peak reductions in FXI levels and activity, with a significant increase in activated partial thromboplastin time [5] - A Phase II study has been initiated to evaluate the safety and efficacy of SRSD107 for preventing venous thromboembolism in patients undergoing total knee arthroplasty [6] Recent Achievements - CRISPR Therapeutics, in partnership with Vertex Pharmaceuticals, received approval for Casgevy, a CRISPR/Cas9 gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia, marking a significant milestone in medical science [8] - Vertex leads the global development and commercialization of Casgevy, sharing costs and profits with CRISPR in a 60:40 ratio [9]

Core Points - The article does not provide any specific insights or analysis related to companies or industries, focusing instead on the author's qualifications and disclosures [1][2][3]. Summary by Categories - **Author's Background**: The author has an extensive educational background in Electronics and Telecommunication Engineering, Computer Science, Business Management, and Computer Applications, with degrees from institutions in Ecuador, the USA, and Spain [1]. - **Disclosure of Interests**: The author discloses that there are no current stock or derivative positions in any mentioned companies and has no plans to initiate any such positions in the near future [2]. - **Seeking Alpha's Position**: The article clarifies that past performance does not guarantee future results and that the views expressed may not reflect those of Seeking Alpha as a whole [3].